Stay updated with breaking news from Treating Fields. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Novocure today announced its participation in the European Society for Medical Oncology (ESMO) Congress 2023 from October 20 ? 24 in Madrid. Novocure will present three new posters on Tumor Treating Fields (TTFields) therapy, including an analysis...
Novocure today announced its participation in the upcoming American Society for Radiation Oncology 2023 Annual Meeting from October 1 – 4 in San Diego. Presentations will describe preclinical,...
Novocure (NASDAQ:NVCR) today announced its participation in the upcoming American Society for Radiation Oncology (ASTRO) 2023 Annual Meeting from October 1 – 4 in San Diego. Presentations will describe preclinical,
ROOT, Switzerland, September 29, 2023--Novocure (NASDAQ: NVCR) today announced its participation in the upcoming American Society for Radiation Oncology (ASTRO) 2023 Annual Meeting from October 1 – 4 in San Diego. Presentations will describe preclinical, clinical and simulation modeling studies on Tumor Treating Fields (TTFields) therapy, including new insights about methods to optimize TTFields intensities delivered at the target tumor during treatment.
1. The median OS was 13.2 months with TTFields arm vs 9.9 months with standard arm, with an HR of 0.74. This effect was more pronounced in treatment with immune checkpoint inhibitors. 2. Most frequent TTFields therapy-related adverse events were grade 1 to 2 skin related events Evidence Rating Level: 1 (Excellent) Study Rundown: Metastatic